Korea's IPO pop is gone: Q3 debuts average minus 4.62% after Q2's 132%

The number that should govern allocation decisions in Seoul is not a quarterly average. It is 0.17%: the share of bids in Skylabs' institutional book that carried voluntary lockup commitments, the lowest of any listing this year, according to the Korea Exchange data cited by Seoul Economic Daily ^[14]. Inverted, 99.83% of participating demand kept the right to sell on the opening day ^[7]. A book assembled that way does not establish a price. It schedules supply.

That explains the asymmetry between the two quarters better than sentiment does. Second-quarter debuts averaged 132.4% against offering prices while the KOSPI itself rose 67.7% ^[1][5], which made IPO participation a roughly 1.96x levered proxy on the index ^[2]. Leverage does not care about direction. With the KOSPI down 20.45% and the KOSDAQ down 9.72% since last month ^[6], the third quarter's average of minus 4.62% ^[3] is the mild part of the story. HL Genomics fell 58.6% on debut, about 12.7 times the quarterly average loss, and Lemon Healthcare and Delicious traded to roughly half their offering prices ^[4][6]. A 137 point swing in average first-day return between consecutive quarters ^[1] is not a market repricing risk gradually.

Supply scarcity did not cushion any of it, which is the more useful signal. Only 17 companies listed on the KOSPI and KOSDAQ in the first half excluding SPAC mergers and venue transfers, against a decade average of 27, some 37% below ^[9][4]. Proceeds of 1.1 trillion won were down 48.7%, implying about 2.14 trillion won a year earlier ^[10][3], when LG CNS and Seoul Guarantee Insurance were among four large deals; this year K bank has been the only sizable one ^[11]. Fewer deals chasing the same institutional capital should have supported pricing. It did not, so the marginal buyer in the second quarter was not an underweight long-term holder.

Skylabs is where that arithmetic lands on an issuer. It priced at 10,000 won, about 20% under the bottom of a 13,000 to 16,000 won range and the first completed listing this year to price below range ^[13]. Measured from the midpoint, the concession is 31% ^[5]. The discount that used to be handed to day-one buyers is now being taken at the pricing table instead.

November's cornerstone investor system and pre-bookbuilding process aim precisely at the 0.17% problem, allowing pre-allocation against lockups of six months or longer ^[15]. Whether it binds depends on the roughly 40 companies that filed for reviews in the second half, and on Sono International, Goodai Global and Musinsa ^[16]. One caveat on the underlying data: the same account has the KOSDAQ closing at 827.15 while stating the index has stayed below 800 since the 1st of last month ^[8], and the depth of that drawdown is what the IPO desks are actually trading.